Sanofi Pharma Day 2021

October 18, 2021 8:00 AM - 6:00 PM

MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139

Add to Calendar 10/18/2021 8:00:00 AM 10/18/2021 6:00:00 PM Sanofi Pharma Day 2021

Accelerate your emerging company or idea at Sanofi’s 2021 Pharma Days on October 18 & 19.  
 

MassBio’s Pharma Days are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. 

Please note that in-person attendees are required to be fully vaccinated to participate in the event. Additionally, masks will be required in all common areas of the event space except for when eating or drinking; in meeting rooms, attendees can remove masks if they feel comfortable doing so.
 

Engage on October 18 from 8 - 9AM ET | Hear from Sanofi leadership during a fireside chat about how Sanofi is evolving to meet the needs of an ever-changing innovation landscape. This livestreamed session will feature: 

  • John Reed, Executive Vice President, Global Head of Research and Development, Sanofi
  • Alban de La Sablière, Head of Partnering, Sanofi
  • Frank Nestle, Global Head of Research, Sanofi


Discover on October 18 from 3 - 4PM ET | Join Sanofi’s information session for the latest insights on its R&D strategy and therapeutic focus areas in immunology and inflammation (I&I) and cell and gene therapies. This hybrid session will feature:

  • John Bertin, Global Head of the Immunology and Inflammation Research Therapeutic Area, Sanofi
  • Christian Mueller, Global Head of Genomic Medicine Unit, Sanofi


Connect on October 18 & 19 | Meet one-on-one with Sanofi representatives to discuss collaboration opportunities. Sanofi’s specific areas of interest are: 

  • Cell and gene therapies, including gene editing and non-viral delivery technologies 
  • Immunology and inflammation, with a focus on dermatology, respiratory, and gastro-intestinal indications   


Eligibility Guidelines
Sanofi is open to connecting with groundbreaking innovators across all stages of development that have a strong understanding of their technology’s path to product. Sanofi is particularly interested in tangible assets or disruptive technologies.

Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with Sanofi representatives. Please note that these representatives did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed. 

MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139
Global Head of Genomic Medicine Unit, Sanofi
Christian Mueller, Ph.D., is the Global Head of the Genomic Medicine Unit at Sanofi focusing on delivering transformative treatments for both rare and common diseases using viral, non-viral and cell therapies. As a former tenured faculty at the University of Massachusetts Medical Center, Dr. Mueller had a distinguished academic research career becoming an established thought leader in gene therapy, developing novel vector platforms, gene and base editing approaches, and mechanisms of gene silencing in the liver and CNS. Dr. Mueller has worked on translating AAV mediated gene therapies to the clinic for AATD, Huntington’s Disease and ALS. Notably he was the first to describe regulatory T- cell responses to the AAV capsid in patients, as well as the first to translate AAV mediated RNAi into the clinic in SOD1 ALS patients. He has been the recipient of many honors and awards for his research, including the Bettina Irvine Family Award for Excellence in Alpha-1 Research, and the ALS Angel Fund Angel Award.  In 2017, he was honored for holding one of the top 12 patents in Massachusetts by the Boston Patent Law Association, for inventing dual function AAV vectors with a silence and replace modality, among many other recognitions of his work. He is also the scientific founder and board member of Apic Bio and scientific founder of Tuned Therapeutics. Dr. Mueller received his Ph.D. in genetics from the University of Florida and M.Sc. in clinical investigation from the University of Massachusetts as Parker B. Francis Fellow.

Brought to you by